Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm

Completed

Conditions studied: Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma

In brief

This protocol will evaluate microRNA biomarkers in blood and fine-needle aspirate biopsies (FNAB) of thyroid nodules. MicroRNA profiles will be determined and evaluated for their utility in pre-operative diagnosis, in particular to distinguish benign from malignant throid neoplasms. Post-surgical fresh-frozen thyroid cancer tissue will be assessed for somatic mutations, mRNA, and microRNA expression patterns. FFPE tissue will be used to obtain H\&E and unstained slides to specific biomarker results using immunohistochemistry.

Key facts

Study ID

NCT01433809

Run by

Norman Eberhardt

People needed

1

Starts

2011-06-01

Expected to finish

2013-05-01

Last updated by the study team

2014-01-22

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with palpable thyroid nodule suspicious for thyroid neoplasm
• Patient selected to undergo fine needle biopsy for cytologic diagnosis
• Male (18 years of age or older)
• Female (18 years of age or older)

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.